Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pneumococcal vaccine GSK2830930A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Pn Group | EXPERIMENTAL | Toddlers 12-23 months of age receiving GSK2830930A vaccine. |
| Control Group | ACTIVE_COMPARATOR | Toddlers 12-23 months of age receiving Synflorix. |
| Name | Type | Description |
|---|---|---|
| Pneumococcal vaccine GSK2830930A | BIOLOGICAL | 1 dose administered intramuscularly |
| Synflorix™ | BIOLOGICAL | 1 dose administered intramuscularly |
Inclusion Criteria: * Subjects who the investigator believes that their parent(s)/Legally Acceptable Representative(s) (LARs) can and will comply with the requirements of the protocol. * A male or female between, and including 12 to 23 months of age at the time of vaccination. * Written informed co...
Pneumococcal vaccine GSK2830930A is an investigational vaccine developed by GSK plc for streptococcal infections. It is a Phase 1 candidate studied in toddlers, and it has been evaluated in a single completed clinical trial. It is not an approved product.
Pneumococcal vaccine GSK2830930A is being studied for the prevention of streptococcal infections. Its only recorded clinical trial enrolled healthy toddlers aged 12 months and older in Germany. The vaccine remains investigational and is not approved for use.
Pneumococcal vaccine GSK2830930A is developed by GSK plc, which trades under the ticker GSK. GSK Biologicals conducted the clinical work on the candidate. No other developer or partner is associated with the asset.
Pneumococcal vaccine GSK2830930A is in Phase 1 development. Its single trial, NCT01485406, has been completed, and no trials are currently active. The vaccine is investigational and has not been approved by the FDA or any other regulator.
Pneumococcal vaccine GSK2830930A has been studied in one clinical trial, NCT01485406, titled a safety and immunogenicity study of GSK Biologicals' pneumococcal vaccine 2830930A administered in toddlers. The Phase 1 trial was completed, enrolled 61 participants in Germany, and used a randomized, double-blind, active-controlled design.